Buy low sell high, $VKTX What Analyst’s have to
Post# of 22755
Posted On: 04/12/2016 3:10:04 PM
Buy low sell high, $VKTX
What Analyst’s have to say about Viking Therapeutics, Inc ($VKTX)?
Author: Author Simon HoldsworthPosted On: Posted on April 12, 2016
The American Red Cross
Wall Street analysts have favorable assessment of Viking Therapeutics, Inc. (VKTX), with a mean rating of 1.8. The stock is rated as buy by 1 analysts, with 3 outperform and 0 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.
For the current quarter, the 3 analysts offering adjusted EPS forecast have a consensus estimate of $-0.48 a share, which would compare with $-1.4 in the same quarter last year. They have a high estimate of $-0.45 and a low estimate of $-0.52.
For the full year, 3 Wall Street analysts forecast this company would deliver earnings of $-1.63 per share, with a high estimate of $-1.52 and a low estimate of $-1.82. It had reported earnings per share of $-1.63 in the corresponding quarter of the previous year.
The analysts project the company to maintain annual growth of around 40 percent over the next five years as compared to an average growth rate of 25.9 percent expected for its competitors in the same industry.
Among the 3 analysts Thomson/First Call tracks, the 12-month average price target for VKTX is $11.75 but some analysts are projecting the price to go as high as $20. If the optimistic analysts are correct, that represents a 1393 percent upside potential from the recent closing price of $1.34. Some sell-side analysts, particularly the bearish ones, have called for $6 price targets on shares of Viking Therapeutics, Inc..
In the last reported results, the company reported earnings of $-0.56 per share, while analysts were calling for share earnings of $-0.44. It was an earnings surprise of -27.3 percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which has completed Phase I trial for the treatment of cancer cachexia, a disease characterized by an uncontrolled decline in muscle mass. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as other preclinical programs for metabolic diseases and anemia. The company has research collaboration with Kennedy Krieger Institute. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
What Analyst’s have to say about Viking Therapeutics, Inc ($VKTX)?
Author: Author Simon HoldsworthPosted On: Posted on April 12, 2016
The American Red Cross
Wall Street analysts have favorable assessment of Viking Therapeutics, Inc. (VKTX), with a mean rating of 1.8. The stock is rated as buy by 1 analysts, with 3 outperform and 0 hold rating. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for strong sell.
For the current quarter, the 3 analysts offering adjusted EPS forecast have a consensus estimate of $-0.48 a share, which would compare with $-1.4 in the same quarter last year. They have a high estimate of $-0.45 and a low estimate of $-0.52.
For the full year, 3 Wall Street analysts forecast this company would deliver earnings of $-1.63 per share, with a high estimate of $-1.52 and a low estimate of $-1.82. It had reported earnings per share of $-1.63 in the corresponding quarter of the previous year.
The analysts project the company to maintain annual growth of around 40 percent over the next five years as compared to an average growth rate of 25.9 percent expected for its competitors in the same industry.
Among the 3 analysts Thomson/First Call tracks, the 12-month average price target for VKTX is $11.75 but some analysts are projecting the price to go as high as $20. If the optimistic analysts are correct, that represents a 1393 percent upside potential from the recent closing price of $1.34. Some sell-side analysts, particularly the bearish ones, have called for $6 price targets on shares of Viking Therapeutics, Inc..
In the last reported results, the company reported earnings of $-0.56 per share, while analysts were calling for share earnings of $-0.44. It was an earnings surprise of -27.3 percent. In the matter of earnings surprises, the term Cockroach Effect is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which has completed Phase I trial for the treatment of cancer cachexia, a disease characterized by an uncontrolled decline in muscle mass. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as other preclinical programs for metabolic diseases and anemia. The company has research collaboration with Kennedy Krieger Institute. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼